Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Zhejiang Int'l Medicine Co., Ltd., commonly referred to as Zhejiang Medicine, is a prominent player in the pharmaceutical industry, headquartered in China. Established in 1995, the company has made significant strides in the development and distribution of high-quality medicinal products, primarily focusing on APIs (Active Pharmaceutical Ingredients) and finished dosage forms.
With a strong operational presence across Asia and expanding into international markets, Zhejiang Medicine is renowned for its commitment to innovation and quality. The company’s core offerings include a diverse range of generic drugs and specialty pharmaceuticals, distinguished by their adherence to stringent regulatory standards.
Recognised for its robust market position, Zhejiang Int'l Medicine has achieved notable milestones, including certifications from global health authorities, which underscore its dedication to excellence in healthcare solutions.
-19 vs industry average
Zhejiang Int'l Medicine Co., Ltd.’s score of 23 is lower than 35% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Zhejiang Int'l Medicine Co., Ltd. yet.
Zhejiang Int'l Medicine Co., Ltd., headquartered in China, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Zhejiang Int'l Group Co., Ltd., which may influence its climate commitments and reporting practices.
While there are no documented reduction targets or climate pledges from Zhejiang Int'l Medicine Co., Ltd., it is important to note that emissions data may be inherited from its parent company, Zhejiang Int'l Group Co., Ltd. This relationship could potentially provide insights into broader corporate sustainability initiatives and emissions management strategies.
As of now, the company has not established specific science-based targets (SBTi) or other industry-standard reduction initiatives. The lack of reported emissions data and reduction commitments highlights a potential area for improvement in transparency and accountability regarding climate impact.
No climate goals have been disclosed for Zhejiang Int'l Medicine Co., Ltd. yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Zhejiang Int'l Medicine Co., Ltd. yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more